Company intelligence / Profile preview

TheraPharm

Baar, Switzerland

Ownership: Private
Development stage: Other

Overview

Lead clinical asset is 90Y-besilesomab/anti-CD66 MTR, developed for safer conditioning in stem cell transplantation for hematologic malignancies and rare diseases, with demonstrated progress in collaboration with University of Southampton; broader diagnostic/therapeutic applications in inflammatory diseases and metastases are supported by clinical data and patents.

Therapeutic areas: OncologyRare DiseasesHematologyImmunology
Modalities: Monoclonal antibodyRadiopharmaceutical
Industry: Biotech

Partnerships

University of Southampton (academic collaboration, clinical translation)

Beyond the preview

Go deeper on TheraPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraPharm.

Explore the full profile